<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412201</url>
  </required_header>
  <id_info>
    <org_study_id>CHF201701</org_study_id>
    <nct_id>NCT03412201</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies</brief_title>
  <acronym>STRONG-HF</acronym>
  <official_title>Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpitaux Universitaires Saint-Louis-Lariboisière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Momentum Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inserm UMRS 942</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STRONG-HF is a multicenter, randomized, parallel group study designed to evaluate the&#xD;
      efficacy and safety of up-titration of standard oral heart failure medications during&#xD;
      hospitalization for acute heart failure. Patients admitted for acute heart failure will be&#xD;
      randomized within 2 days before discharge to either usual care or intensification of&#xD;
      treatment with a beta-blocker, a renin-angiotensin system blocker, and a mineralocorticoid&#xD;
      receptor blocker (&quot;high intensity care&quot; arm). In the &quot;high intensity care&quot; arm, patients'&#xD;
      clinical signs and symptoms of heart failure will be assessed, and routine laboratory&#xD;
      measures and biomarkers will be measured, at frequent post-discharge visits. When these&#xD;
      measures indicate that it is safe to do so, the doses of the oral heart failure medications&#xD;
      will be increased to optimal levels. Patients will be followed through 180 days from&#xD;
      randomization. Patients assigned to the usual care group will be followed by their general&#xD;
      physician and/or cardiologist according to local medical standards. Patients who were&#xD;
      screened but did not meet eligibility criteria will be followed for 90-day outcome.&#xD;
      Randomized patients will be contacted at 180 days to assess outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STRONG-HF is a multicenter, randomized, parallel group study designed to evaluate the&#xD;
      efficacy and safety of up-titration of standard of care medical therapy including&#xD;
      beta-blockers; angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blocker&#xD;
      (ARB) or angiotensin receptor neprolysin inhibitor (ARNi); and mineralocorticoid receptor&#xD;
      antagonist (MRAs), on morbidity and mortality when initiated and up-titrated early during&#xD;
      hospitalization for acute heart failure (AHF). Optimal safety conditions will allow&#xD;
      physicians to introduce and/or continue oral HF therapies during this &quot;vulnerable phase&quot; in&#xD;
      AHF patients. Patients admitted for AHF with clinical signs of congestion and elevated&#xD;
      circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP) and who are not treated&#xD;
      with optimal doses of oral heart failure (HF) therapies within 2 days before hospital&#xD;
      discharge for AHF and who are hemodynamically stable will be randomized in a 1:1 ratio to&#xD;
      either usual care (named &quot;usual care&quot; arm) or intensification of treatment with&#xD;
      beta-blockers, and ACEi (or ARB) or ARNi and a MRA (named &quot;high intensity care&quot; arm). In the&#xD;
      latter arm, repeated assessments of clinical signs and symptoms of heart failure, routine&#xD;
      clinical laboratory measures including potassium, sodium, and creatinine as well as NT-ProBNP&#xD;
      will foster, encourage and ensure the safety of the optimization of oral heart failure&#xD;
      therapies. AHF patients who were screened but did not meet inclusion criteria, including low&#xD;
      circulating NT-proBNP at visit 2, will be followed for 90-day outcome. Randomized patients&#xD;
      will be contacted at 180 days to assess outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter, randomized, parallel group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>180-day all-cause mortality or heart failure readmission</measure>
    <time_frame>180 days</time_frame>
    <description>Cumulative risk of either readmission for heart failure or death at 180 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline to 90 days in quality of life as measured using the EQ-5D visual analogue scale (VAS) which ranges from 0 to 100 with a higher score representing a better outcome. &quot;EQ-5D&quot; is the official name of a quality of life instrument developed by EuroQol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180-day all-cause mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Cumulative risk of death at 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day all-cause mortality or heart failure readmission</measure>
    <time_frame>90 days</time_frame>
    <description>Cumulative risk of either readmission for heart failure or death at 90 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>180-day cardiovascular death</measure>
    <time_frame>180 days</time_frame>
    <description>Cumulative risk of death due to cardiovascular cause at 180 days</description>
  </other_outcome>
  <other_outcome>
    <measure>90-day cardiovascular death</measure>
    <time_frame>90 days</time_frame>
    <description>Cumulative risk of death due to cardiovascular cause at 90 days</description>
  </other_outcome>
  <other_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Cumulative risk of death at 90 days</description>
  </other_outcome>
  <other_outcome>
    <measure>180-day heart failure readmission</measure>
    <time_frame>180 days</time_frame>
    <description>Cumulative risk of readmission for heart failure at 180 days</description>
  </other_outcome>
  <other_outcome>
    <measure>90-day heart failure readmission</measure>
    <time_frame>90 days</time_frame>
    <description>Cumulative risk of readmission for heart failure at 90 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Finkelstein-Schoenfeld hierarchical composite</measure>
    <time_frame>90 days</time_frame>
    <description>Hierarchical composite endpoint comprising death, heart failure readmissions, and EQ-VAS analyzed using Finkelstein-Schoenfeld methodology</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline to 90 days in NT-proBNP on the log scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in weight</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline to 90 days in weight in kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in signs and symptoms of congestion: NYHA class</measure>
    <time_frame>90 days</time_frame>
    <description>Changes from baseline to 90 days in New York Heart Association (NYHA) class which ranges from 1 to 4 with a higher class representing a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in signs and symptoms of congestion: orthopnea</measure>
    <time_frame>90 days</time_frame>
    <description>Changes from baseline to 90 days in orthopnea rated on a scale from 0 to 3 with a higher score representing a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in signs and symptoms of congestion: peripheral edema</measure>
    <time_frame>90 days</time_frame>
    <description>Changes from baseline to 90 days in peripheral edema rated on a scale from 0 to 3 with a higher score representing a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in signs and symptoms of congestion: rales</measure>
    <time_frame>90 days</time_frame>
    <description>Changes from baseline to 90 days in rales rated on a scale from 0 to 3 with a higher score representing a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in signs and symptoms of congestion: JVP</measure>
    <time_frame>90 days</time_frame>
    <description>Changes from baseline to 90 days in jugular venous pulse (JVP) rated on a scale from 1 to 4 with a higher score representing a worse outcome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Intensity Care</intervention_name>
    <description>Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.</description>
    <arm_group_label>High Intensity Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospital admission within the 72 hours prior to Screening for acute heart failure with&#xD;
             dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and/or&#xD;
             symptoms of heart failure such as edema and/or positive rales on auscultation.&#xD;
&#xD;
          2. All measures within 24 hours prior to Randomization of systolic blood pressure ≥ 100&#xD;
             mmHg, and of heart rate ≥ 60 bpm.&#xD;
&#xD;
          3. All measures within 24 hours prior to Randomization of serum potassium ≤ 5.0 mEq/L&#xD;
             (mmol/L).&#xD;
&#xD;
          4. Biomarker criteria for persistent congestion:&#xD;
&#xD;
          5. At Screening, NT-proBNP &gt; 2,500 pg/mL.&#xD;
&#xD;
          6. At the time of Randomization (within 2 days prior to discharge), NT-proBNP &gt; 1,500&#xD;
             pg/mL (to ensure the persistence of congestion) that has decreased by more than 10%&#xD;
             compared to Screening (to ensure the acuity of the index episode).&#xD;
&#xD;
          7. At 1 week prior to admission, at Screening, and at Visit 2 (just prior to&#xD;
             Randomization) either (a) &lt;= ½ the optimal dose of ACEi/ARB/ARNi (see Table)&#xD;
             prescribed, no beta-blocker prescribed, and &lt;= ½ the optimal dose of MRA prescribed or&#xD;
             (b) no ACEi/ARB/ARNi prescribed, &lt;= ½ the optimal dose of beta-blocker prescribed, and&#xD;
             &lt;= ½ the optimal dose of MRA prescribed.&#xD;
&#xD;
          8. Written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 or &gt; 85 years.&#xD;
&#xD;
          2. Clearly documented intolerance to high doses of beta-blockers.&#xD;
&#xD;
          3. Clearly documented intolerance to high doses of renin-angiotensin system (RAS)&#xD;
             blockers (both ACEi and ARB).&#xD;
&#xD;
          4. Mechanical ventilation [not including continuous positive airway pressure&#xD;
             (CPAP)/bilevel positive airway pressure (BIPAP)] in the 24 hours prior to Screening.&#xD;
&#xD;
          5. Significant pulmonary disease contributing substantially to the patients' dyspnea such&#xD;
             as forced expiratory volume during the 1st second (FEV1)&lt; 1 liter or need for chronic&#xD;
             systemic or nonsystemic steroid therapy, or any kind of primary right heart failure&#xD;
             such as primary pulmonary hypertension or recurrent pulmonary embolism.&#xD;
&#xD;
          6. Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac&#xD;
             resynchronization therapy (CRT) device implantation within 3 months, or percutaneous&#xD;
             transluminal coronary intervention (PTCI), within 1 month prior to Screening.&#xD;
&#xD;
          7. Index Event (admission for AHF) triggered primarily by a correctable etiology such as&#xD;
             significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial&#xD;
             fibrillation/flutter with sustained ventricular response &gt;130 beats per minute, or&#xD;
             bradycardia with sustained ventricular arrhythmia &lt;45 beats per minute), infection,&#xD;
             severe anemia, acute coronary syndrome, pulmonary embolism, exacerbation of chronic&#xD;
             obstructive pulmonary disease (COPD), planned admission for device implantation or&#xD;
             severe non-adherence leading to very significant fluid accumulation prior to admission&#xD;
             and brisk diuresis after admission. Troponin elevations without other evidence of an&#xD;
             acute coronary syndrome are not an exclusion.&#xD;
&#xD;
          8. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic&#xD;
             obstructive cardiomyopathy.&#xD;
&#xD;
          9. History of heart transplant or on a transplant list, or using or planned to be&#xD;
             implanted with a ventricular assist device.&#xD;
&#xD;
         10. Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to&#xD;
             screening that is untreated.&#xD;
&#xD;
         11. Presence at Screening of any hemodynamically significant valvular stenosis or&#xD;
             regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular&#xD;
             dilatation, or the presence of any hemodynamically significant obstructive lesion of&#xD;
             the left ventricular outflow tract.&#xD;
&#xD;
         12. Active infection at any time during the AHF hospitalization prior to Randomization&#xD;
             based on abnormal temperature and elevated white blood cells (WBC) or need for&#xD;
             intravenous antibiotics.&#xD;
&#xD;
         13. Stroke or transient ischemic attack (TIA) within the 3 months prior to Screening.&#xD;
&#xD;
         14. Primary liver disease considered to be life threatening.&#xD;
&#xD;
         15. Renal disease or estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2 [as&#xD;
             estimated by the simplified Modification of Diet in Renal Disease (MDRD) formula] at&#xD;
             Screening or history of dialysis.&#xD;
&#xD;
         16. Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a&#xD;
             life expectancy &lt; 6 months.&#xD;
&#xD;
         17. Prior (defined as less than 30 days from screening) or current enrollment in a&#xD;
             congestive heart failure (CHF) trial or participation in an investigational drug or&#xD;
             device study within the 30 days prior to screening&#xD;
&#xD;
         18. Discharge for the AHF hospitalization anticipated to be &gt; 14 days from admission, or&#xD;
             to a long-term care facility. Randomization must occur within 12 days following&#xD;
             admission and within 2 days prior to anticipated discharge.&#xD;
&#xD;
         19. Inability to comply with all study requirements, due to major co-morbidities, social&#xD;
             or financial issues, or a history of noncompliance with medical regimens, that might&#xD;
             compromise the patient's ability to understand and/or comply with the protocol&#xD;
             instructions or follow-up procedures&#xD;
&#xD;
         20. Pregnant or nursing (lactating) women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Mebazaa, MD PhD FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inserm UMRS 942; Hôpitaux Universitaires Saint-Louis-Lariboisière, University Paris Diderot</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Novosadova, MD</last_name>
    <phone>+41614851250</phone>
    <email>marianovosadova@momentum-research.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sanatorio de la Canada</name>
      <address>
        <city>Villa María</city>
        <state>Cordoba</state>
        <zip>X5900JKA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Novosadova, MD</last_name>
      <phone>1614851250</phone>
      <phone_ext>4</phone_ext>
      <email>marianovosadova@momentum-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chutro Srl Clinic</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Del Prado Private Clinic</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Roque Hospital</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosario Cardiovascular Institute</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosario Clinical Research Institute - Delta</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Modelo Cardiology Center</name>
      <address>
        <city>San Miguel De Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Treatment Medical Clinic SA</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Angel Hominal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Rosa Hospital</name>
      <address>
        <city>Santa Rosa</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Martin SA Clinic</name>
      <address>
        <city>Venado Tuerto</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fusavim Privada SRL Clinic</name>
      <address>
        <city>Villa María</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internal Med. 1, St. Josef Hospital Braunau</name>
      <address>
        <city>Braunau Am Inn</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clin. Dep. Internal Med 3, University Hospital St. Poelten</name>
      <address>
        <city>St. Poelten</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Internal Med., LKH Villach</name>
      <address>
        <city>Villach</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>1. Med. Dep, Donauspital</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cardiology Department at Hietzing Hospital with Neurological Center Rosenhugel</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dep. Of Cardiology, Medical Univ. Vienna</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Diagnostic Center</name>
      <address>
        <city>Cartagena</city>
        <state>Bolivar</state>
        <zip>130001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Gabriel Manzur Jattín</last_name>
      <phone>3157315055</phone>
      <phone_ext>57</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEQUIN Cardiomet Foundation</name>
      <address>
        <city>Armenia</city>
        <state>Quindio</state>
        <zip>630004</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregorio Sánchez Vallejo</last_name>
      <phone>3104527096</phone>
      <phone_ext>57</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiomet Pereira Clinical Research Center Foundation</name>
      <address>
        <city>Pereira</city>
        <state>Risaralda</state>
        <zip>660003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Hernando Garcia Ortiz</last_name>
      <phone>3116111</phone>
      <phone_ext>57</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santander Ophthalmological Foundation</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <zip>681004</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Diego Higuera Cobos</last_name>
      <phone>3162791839</phone>
      <phone_ext>57</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auxerre Hospital Center</name>
      <address>
        <city>Auxerre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Beziers</name>
      <address>
        <city>Béziers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Center Hospital Regional University of Tours Trousseu Hospital</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Henri Mondor</name>
      <address>
        <city>Creil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Burgundy F. Mitterand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Saint-Louis-Lariboisière, University Paris Diderot</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Center Hospital of Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Buda Hospital of the Hospitaller Order of Saint John of God</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Kanizsai Dorottya Hospital</name>
      <address>
        <city>Nagykanizsa</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Rafael Hospital in Zala County</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Barzilay MC Ashkelon</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe MC</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dept of Medicine Research unit, Maputo Central Hospital</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mavalane Hospital, National Institute of Health</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Amino Kano Teaching Hospital</name>
      <address>
        <city>Kano</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Murtala Muhammad Specialist Hospital</name>
      <address>
        <city>Kano</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget HealthCare Institution &quot;First City clinical hospital named after E.E. Volosevich&quot;</name>
      <address>
        <city>Arkhangel'sk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional budget Healthcare Institution &quot;Cardiological dispensary&quot;</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Educational Institution of Higher Education &quot;Moscow State Medico-Dental University n.a. A.I. Evdokimov&quot;, under Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Educational Institution of Higher Education &quot;Moscow State University n.a. M.V. Lomonosov&quot;, independent division Medical research Educational Centre</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Moscow City Hospital # 81, Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow State Budget Healthcare Institution City clinical Hospital 52 of Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Unit of the RF Ministry of Internal Affairs in Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University n.a. N.I.Pirogov based at City Clinical hospital n.a. V.M.Buyanov DZM</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI of Moscow City clinical hospital 64 of Moscow Healthcare department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget HealthCare Institution of Moscow &quot;City clinical hospital 15 n.a. O.M. Filatov under Department of HealthCare of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget HealthCare Institution of Moscow &quot;City clinical hospital 29 n.a. N.E. Bauman under Department of HealthCare of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget HealthCare Institution of Mosocw &quot;City clinical hospital 51 under Department of HealthCare of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget HealthCare Institution &quot;City hospital 38 n.a. N.A. Semashko&quot;</name>
      <address>
        <city>Pushkin</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Municipal Government-financed Institution of Healthcare &quot;City Emergency Hospital&quot; of Rostov-on-Don City</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Ryazan State Medical University named after academician I.P. Pavlov&quot;</name>
      <address>
        <city>Ryazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Educational Institution of Higher Education &quot;North-West state medical university n.a. I.I. Mechnikov under the Ministry of Health of the Russian Federation&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budget Healthcare Institution Pokrovskaya City Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget Healthcare Institution City Hospital 15</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot;Saint Petersburg state budget research institution of first aid named after I. I. Dzhanelidze&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget HealthCare Institution of Vladimir Region &quot;City Hospital 4 of Vladimir&quot;</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare of Yaroslavl Region &quot;Clinical Hospital 8&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardio and Vascular Diseases</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>V. Internal Clinic, LFUK and UNB Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Internal Department, Hospital with Polyclinic Brezno</name>
      <address>
        <city>Brezno</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Internal Department, Dolnooravian Hospital of Dr. L.N.Jege</name>
      <address>
        <city>Dolný Kubín</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Internal Department, Hospital with Polyclinic Lucenec</name>
      <address>
        <city>Lučenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>First Internal Clinic, Faculty Hospital with Polyclinic Nove Zamky</name>
      <address>
        <city>Nové Zámky</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine Hospital Rimavska Sobota</name>
      <address>
        <city>Rimavská Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine UVN SNP-FN</name>
      <address>
        <city>Ružomberok</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Internal Department, NsP Spisska Nova Ves</name>
      <address>
        <city>Spišská Nová Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Internal Department Hospital Arm General L. Svobodu Svidnik</name>
      <address>
        <city>Svidník</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Nelson Mandela Academic Hospital, Walter Sisulu University</name>
      <address>
        <city>Mthatha</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Habib Bougatfa Hospital</name>
      <address>
        <city>Bizerte</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Jendouba</name>
      <address>
        <city>Jendouba</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fattouma Bourguiba Hospital</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hedi chaker Hospital</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Charles Nicolle Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Habib Thameur Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>La Rabta Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Military Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Mozambique</country>
    <country>Nigeria</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disease management</keyword>
  <keyword>Medication therapy management</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

